Warning

We strongly advise you to register via our website only and by using the official registration form.
Also to reserve your accommodation using the hotel conference link which you find on our official event page.
Please be aware of fraudulent third party websites. Some companies may mislead event participants by posing as the official congress organisers and may use a range of deceptive tactics including usage of our logos.

The Joint 24^th Medicines for Europe and 21^st IGBA Annual Conference will bring together over 300 experts including medicine manufacturers, stakeholders and governments to evaluate market trends, innovative commercial strategies, challenges for the pharmaceutical sector and new opportunities to improve access to medicines for patients. At this unique event, the participants will not only gain new information, but will also have the opportunity to network in the beautiful capital of Hungary, Budapest!

CHAIRPERSONS AND SPEAKERS

Chester “Chip” Davis, Jr.

President and Chief Executive Officer - aam

László György

Minister of State for Economic Strategy and Regulation - Hungary

Knut Slatten

Vice President, Senior Analyst - Moody's Investors Service

Simon Goeller

Partner - McKinsey

Jeff Watson

President and Chief Operating Officer - Apotex Inc.

Jacek Glinka

President, European Region - Mylan

Christoph Stoller

General Manager Cluster Germany & Austria - Teva-ratiopharm and Vice President - Medicines for Europe

Lisa Günther

Head Global Business Insights - Sandoz International GmbH

Frank Bouisset

Head Specialty Franchises West Europe - Sandoz and Chairman of the Hospital Channel WG - Medicines for Europe

Gergely Németh

Project Manager - National Institute of Health Insurance Fund Management (NEAK)

Martin Favié

Chairman - Bogin (Dutch Biosimilars and Generic Medicines Association)

Monika Dereque-Pois

Director General - GIRP

Brendan Cuddy

Head Manufacturing and Quality Compliance Service - EMA

David R. Gaugh, R.Ph.

Senior Vice President for Sciences and Regulatory Affairs - Association for Accessible Medicines (aam)

Riccardo Luigetti

Principal International Affairs Officer - European Medicines Agency (EMA)

David Jauch

Director Government Relations - Fresenius Kabi

Jim Keon

President - Canadian Generic Pharmaceutical Association (CGPA) and President - Biosimilars Canada

Alison Cave

Principal Scientific Administrator - European Medicines Agency

Frederik Van Remoortel

Lawyer - Crowell & Moring

Michaeline Daboul

President & CEO - MediSpend

Dilip G Shah

Secretary General - IPA

Victor Lino Mendonça

Head of Policy and Market Access Europe - Mylan

Ana-Eva Ampélas

Head of Unit for Medical Products: Quality, Safety, Innovation in Unit B4 - DG SANTE, European Commission

Ulrike Kreysa

Senior Vice President Healthcare - GS1 Healthcare

Craig Stobie

Director Global Sector Management - Domino

Umberto Comberiati

Head of Marketing Europe - Teva Pharmaceuticals and Chair Value Added Medicines Sector Group

Mariano Votta

Director – Active Citizenship Network and Responsible for EU Affairs - Italian NGO Cittadinanzattiva

Michael Soldan

Senior Vice President Head of Biosimilars - Fresenius Kabi

Zoltán Kaló

Professor of Health Economics - Eötvös Loránd University (ELTE), Budapest, Hungary

Erik Bogsch

Head R&D & Manufacturing within the Biotechnology Business Unit - Gedeon Richter Plc

Christine Simmon

Senior Vice President of Policy and Strategic Alliances - aam

Markus Sieger

CEO - Polpharma Group

Aidan Fry

Editor - Generics Bulletin, Informa

Christiane Hanke-Harloff

Head of the Biotechnology Business Unit - Gedeon Richter

Jamie Wilkinson

Director of Professional Affairs - PGEU

Bernd Grabner

Director - Jacoby GM Pharma GmbH and Vice-President - PHAGO

Why you should attend the conference!

Get updates on the latest development and market trends in the Generic, Biosimilar and Value Added medicines industry
Meet high-level speakers from Europe, Brazil, US, Japan, Taiwan, Russia, Canada, Malaysia, South Africa, India and many more countries to understand the global relevance of Generic, Biosimilar and Value Added Medicines
Network with policy-makers, regulators, payers and peers
Discover business opportunities in pharmaceutical markets across the world

Session Topics will cover:

Sustainability of the off-patent markets
Political decisions impacting the supply of medicines
The fight against counterfeit medicines
How to keep up in providing data, recognising its value and making the best use of it
How to manage selective transparency, commoditisation, shortages
The impact of international agreements on access to medicines
Models to bring better medicines to patients
Defining a future where trust and regulatory efficiency translate into patient access
Increasing patient access to specialty medicines

See here the companies/organisations that attended the 2017 edition!

To secure your place at this ‘must attend’ platform, please register by January 2018 and you too can share information with leading experts and network with your peers.

Follow the event on Twitter

#IGBAMedicinesforEU

PLATINUM SPONSOR

GOLD SPONSORS

SILVER SPONSOR

Medicines for Europe is honored to be collaborating with the following partners to make this year’s conference

CONTACT

Lucia Romagnoli
M: +44 (0) 7 562 87 68 73

For more information on advertising, exhibition and sponsorship packages:
Trudy Beks
M: +31 6 4119 0824

Media Requirements and Press Policy
For any other media enquiries:
Andrea Bedorin
P: +32 (0)2 533 20 11

Global Generic, Biosimilar and
Value Added Medicines Conference
Joint 24^th Medicines for Europe and 21^st IGBA Annual Conference

Hilton Budapest Hotel, Budapest

13 June 2018 - 15 June 2018

Warning

CHAIRPERSONS AND SPEAKERS

Why you should attend the conference!

Session Topics will cover:

#IGBAMedicinesforEU

PLATINUM SPONSOR

GOLD SPONSORS

SILVER SPONSOR

Medicines for Europe is honored to be collaborating with the following partners to make this year’s conference

CONTACT

Share on Mastodon